Pregled bibliografske jedinice broj: 208381
Molecular diagnostics: challenges and possibilities
Molecular diagnostics: challenges and possibilities // Acta Medica Croatica / Radman, Ivo (ur.).
Zagreb: Akademija medicinskih znanosti Hrvatske, 2005. str. 64-64 (pozvano predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 208381 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Molecular diagnostics: challenges and possibilities
Autori
Sertić, Jadranka ; Zadro, Renata ; Božina, Nada
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Acta Medica Croatica
/ Radman, Ivo - Zagreb : Akademija medicinskih znanosti Hrvatske, 2005, 64-64
Skup
1. kongres hrvatskog društva za unapređenje beskrvnog liječenja
Mjesto i datum
Zagreb, Hrvatska, 22.09.2005. - 25.09.2005
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
molecular diagnostics; hemato-oncology; pharmacogenetics; monogenic and polygenic diseases
Sažetak
Modern laboratory diagnostics is characterized by a number of processes, like computerization and robotization, significant development of point-of-care testing (POCT) and molecular diagnostics, application of small amounts of sample (microsampling) and increasingly short turnaround time. Molecular diagnosis and POCT are two segments of laboratory medicine that allow individualized medical approach and high quality of treatment, but also reduce the possibility for diagnostic errors and turnaround time and costs. The quality of laboratory tests is to be implemented at European level by standardization of methods, coordination of activities related to ISO standards, and harmonization of accreditation standards. The application of new technologies in molecular analysis (from PCR to Biochip) allows the diagnosis of an entire range of conditions and diseases, including blood groups, HIV and hepatitis, HLA-typing, prenatal and early diagnosis of hereditary monogenic and polygenic diseases, analysis of tumor markers, diagnosis of infective diseases, hemato-oncologic and coagulation diagnosis and pharmacogenetics. Interindividual differences regarding efficacy and toxicity of pharmacotherapy are often based on genetic variabilities of metabolic enzymes, transport proteins and receptors. Pharmacogenetic analysis may contribute to therapy individualization and optimization. At the end of 2004, AmpliChip CYP450 was approved for use and thus contributed to effective application of various medications. Microsampling, individual approach and possibility of early molecular diagnostics may together contribute to high quality healthcare and reduced therapy costs.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
- MEDLINE